Invitation for public comment - ACMS meeting, July 2013
This consultation closed on 30 May 2013.
Notice inviting public submissions under Regulation 42ZCZK of the Therapeutic Goods Regulations 1990
The delegate of the Secretary of the Department of Health and Ageing hereby gives notice that the proposed amendments to the current Poisons Standard contained in this notice will be referred for scheduling advice to relevant expert advisory committees.
Accordingly, the following scheduling proposals are open for public submissions. Submissions must be relevant to the proposed amendment, must address a matter mentioned in section 52E of the Therapeutic Goods Act 1989 and be received by the closing date.
Persons wishing to make a submission are strongly encouraged to submit them in electronic format (word or unsecured PDF) to the email address provided below by 30 May 2013.
GPO Box 9848
CANBERRA ACT 2601
Facsimile: 02 6289 2650
Public submissions received after the closing date may or may not be considered by the advisory committee(s).
Public submissions must include the name of the person making the submission and preferably an email or postal address.
Please note that the submissions received on or before the closing date will be published following removal of confidential information. It is up to the person making the submission to highlight any information which they wish to be considered as confidential. Material claimed to be commercial-in-confidence will be considered against the guidelines for the use and release of confidential information set out in Chapter 6 of the Scheduling Policy Framework (SPF), issued by the National Coordinating Committee on Therapeutic Goods.
The relevant expert advisory committee(s) will then consider all valid submissions and provide advice to the delegate in relation to the proposed amendment. After considering this advice, the delegate will make an interim scheduling decision. This interim decision is expected to be published on 26 September 2013 at Reasons for scheduling delegate's interim decisions and invitations for further comment and will be open for further submissions from only the applicant and persons who made a submission in response to the original invitation received on or before the closing date. For more information on the scheduling process please see the SPF.
|Loratadine||Proposal to reschedule loratadine from Schedule 2 to unscheduled in oral preparations containing 10mg or less in packs containing not more than 5 daily doses for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, with a warning labels recommending a daily dose not exceeding 10mg loratadine for adults and children with body weight over 30kg, or recommended daily dose not exceeding 5mg loratadine for children with body weight 30kg and under.|
|Vortioxetine hydrobromide||Proposal for new Appendix L entry for Vortioxetine hydrobromide|